You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

TRx0237

Showing 1 - 5 of 5
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Behavioral Variant Frontotemporal Dementia (bvFTD) Trial in Worldwide (TRx0237, Placebo)

Completed
  • Behavioral Variant Frontotemporal Dementia (bvFTD)
  • TRx0237
  • Placebo
  • Los Angeles, California
  • +66 more
Mar 12, 2018

Alzheimer's Disease Trial in Worldwide (TRx0237 200 mg/day, Placebo)

Completed
  • Alzheimer's Disease
  • TRx0237 200 mg/day
  • Placebo
  • Phoenix, Arizona
  • +94 more
Mar 12, 2018

Alzheimer's Disease Trial in Worldwide (TRx0237 150 mg/day, TRx0237 250 mg/day, Placebo)

Completed
  • Alzheimer's Disease
  • TRx0237 150 mg/day
  • +2 more
  • Phoenix, Arizona
  • +120 more
Mar 12, 2018

Diabetes, Type 1 Trial in Canada, United States (Otelixizumab)

Terminated
Has Results
  • Diabetes Mellitus, Type 1
  • Birmingham, Alabama
  • +16 more
Oct 11, 2017

Alzheimer's Disease Trial in Germany, United Kingdom (TRx0237, Placebo)

Terminated
Has Results
  • Alzheimer's Disease
  • TRx0237
  • Placebo
  • Achim, Germany
  • +11 more
Jun 10, 2014